Tempus deal22 Sep 2025 09:31
Use of proceeds from Fundraise
On 15 September 2025 the Company announced that it had signed a collaboration
agreement with Tempus. The collaboration will make the Company's
kidneyintelX.dkd prognostic blood testing more widely available for eligible
patients within its US network of healthcare institutions. Eligible patients
have type 2 diabetes with chronic kidney disease, impacting nearly 15 million
individuals in the US.
That's a lot of money for RENEX